Pfizer's Trading Volume Hits 13.10 Billion, Ranked 96th Amid Patent Lawsuit Resolution and Executive Pay Controversy
1min read On April 3, 2025, Pfizer's trading volume reached 13.10 billion, ranking 96th in the day's stock market. Pfizer's stock price fell by 1.66%.
Pfizer and gsk have resolved their patent lawsuit over RSV vaccines. The companies have agreed to dismiss the case with prejudice, meaning it cannot be refiled. This resolution is expected to reduce legal uncertainties and allow both companies to focus on their respective vaccine development and commercialization efforts.
Pfizer's investors have been advised by ISS to reject the company's executive pay proposal. ISS, a leading proxy advisory firm, has recommended that shareholders vote against the proposal, citing concerns over the compensation structure and its alignment with shareholder interests. This recommendation could potentially impact Pfizer's corporate governance and investor relations.
Ask Aime: "Understanding the impact of Pfizer's legal resolution with GSK on their RSV vaccine development and commercialization."
